4D Molecular Therapeutics Inc (FDMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $689.52M
Last updated: Nov 17, 2026 at 11:06 AM ET
4D Molecular Therapeutics Inc (FDMT) Stock Forecast
Analysts expect 4D Molecular Therapeutics (FDMT) to earn -$4.16 per share in the fiscal year ending Dec 31, 2026, on revenue of $13.25M. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 9 | 75.0% |
| Hold | 1 | 8.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 51.9%.
- Fiscal year ending Dec 31, 2026
- -$4.16
- EPS consensus, revenue $13.25M
- Fiscal year ending Dec 31, 2027
- -$4.10
- EPS consensus, revenue $20.13M
- Next report
- Mar 16, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.16 | -$4.30 to -$4.00 | 11 | $13.25M | $6.80M to $22.50M | 10 |
| Dec 31, 2027 | -$4.10 | -$4.98 to -$3.38 | 10 | $20.13M | N/A | 8 |
Quarterly Estimates
The EPS consensus falls from -$1.10 for the quarter ending Dec 31, 2026 to -$1.13 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.10 | -$1.19 to -$1.00 | 13 | $3.67M | N/A | 11 |
| Mar 31, 2027 | -$1.13 | -$1.19 to -$1.06 | 2 | $2.50M | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.16 | -$4.15 | -$4.15 | -$4.15 | -$4.14 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.10 | -$4.09 | -$4.09 | -$4.08 | -$4.09 | N/A |
| Quarter ending Mar 31, 2027 | -$1.13 | -$1.10 | -$1.10 | -$1.06 | -$1.06 | N/A |
Frequently Asked Questions About FDMT
What is the FDMT stock forecast?
Consensus analyst estimates put 4D Molecular Therapeutics's EPS at -$4.16 for the fiscal year ending Dec 31, 2026, on revenue of $13.25M. The consensus rating from 12 analysts is Buy.
How do analysts rate FDMT stock?
Of 12 analysts covering 4D Molecular Therapeutics, 2 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from FDMT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.16, with estimates from -$4.30 to -$4.00 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.10, with estimates from -$4.98 to -$3.38 from 10 analysts.
What revenue do analysts expect from 4D Molecular Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $13.25M, with estimates from $6.80M to $22.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.13M.
How many analysts cover FDMT?
12 analysts rate 4D Molecular Therapeutics stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
FDMT pages: Overview, Earnings, Forecast, Financials, Competitors